CLDX faces an unusual split this week: the Street is rushing to raise price targets while the stock is falling hard, creating one of the sharpest bull-bear divergences in the biotech space right now.
The analyst activity is striking. At least four firms raised targets in the past 48 hours alone, all maintaining positive ratings. Leerink Partners lifted its target to $88 from $70. Morgan Stanley's Judah Frommer bumped to $57 from $50, his second raise in two weeks. Cantor Fitzgerald moved to $72, and HC Wainwright jumped to $64 from $42. The consensus mean target is now $62.50 — nearly double the current price of $33.51. That gap is too large to dismiss as rounding error. It reflects genuine conviction from the Street that the market is mispricing something, likely the binary risk around barzolvolimab's Phase III data expected later this year.
The stock tells a different story. CLDX closed at $33.51 on Tuesday, down 11.6% on the day and nearly 13% on the week. The one-month loss has reached 17%. Close peers moved in the opposite direction — STOK gained 3.7% on the week, IMNM added 7.5%, and rose 11%. The sector bid was broadly constructive. CLDX's drop was idiosyncratic, not macro-driven.
Positioning in the lending market is notably relaxed given the share price decline. Short interest runs at 12.6% of the free float — a meaningful level — but it has edged lower over the past week and month. More telling is the availability of shares to borrow: at roughly 2,475% of current short interest, there is far more lending supply than demand. The cost to borrow is just 0.54%, ticking up roughly 23% over the week but still firmly in bargain territory. Shorts are not scrambling to establish or defend positions. The short score dipped from 58.3 on September 10 to 55.8 today, suggesting short-side conviction has softened rather than built. This is a stock falling despite, not because of, aggressive short pressure.
Options traders are actually less defensive than usual. The put/call ratio has dropped to 1.03, well below the 20-day average of 1.31 — about one standard deviation lighter on puts. For context, the PCR ran as high as 1.58 in early September. The current reading implies options market participants are not bracing for further sharp declines; if anything, some are using the dip to position for a recovery. That diverges meaningfully from what the price action alone would suggest.
Institutional ownership remains a source of support. Wellington Management holds 12.2% of shares and added roughly 980,000 shares to its position. T. Rowe Price crossed the 6% threshold with a fresh 13G filed in August, having bought nearly 2.6 million shares in the most recent reported period. BlackRock added 1.6 million shares. These are not traders reacting to the week's sell-off — they are longer-dated holders with documented conviction. No 13D activists are on the register. All filings are passive in nature, though stakes are as last disclosed and positions around the 5% threshold can change without triggering a further filing.
The bear case is concentrated in one place: clinical trial risk. Celldex is building its entire near-term value on barzolvolimab succeeding across multiple indications, with the company still burning cash and carrying no meaningful revenue. The valuation multiples confirm it — the price-to-book sits around 4.4x and falling, while PE and EV/EBITDA are both deeply negative. The ORTEX short score rank of 27 out of 100 suggests shorts, relative to peers, are not particularly aggressive. The analyst recommendation divergence score ranks in just the 5th percentile, meaning the Street is unusually aligned in its bullish direction — which can be read as either reassuring or as a crowded consensus with limited capacity to surprise to the upside.
With Q3 results due November 2, the next concrete information event is roughly six weeks away. The gap between analyst targets and the current price — and between the stock's decline and the calm in the borrow market — makes the Phase III read-out timeline the one data point worth tracking most closely.
See the live data behind this article on ORTEX.
Open CLDX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
